Veronica Lombardi

Veronica Lombardi

Auto-generated profile, based on publicly available information

Veronica Lombardi

Department of Biology and Biotechnologies 'Charles Darwin', Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, 00185, Rome, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2025 in Molecular Systems Biology
Verified
Journal Article
Open access
VLVeronica Lombardi
Veronica Lombardi
LRLorenzo Di Rocco
Lorenzo Di Rocco
EMEleonora Meo
Eleonora Meo
VVVeronica Venafra
Veronica Venafra
ENElena Di Nisio
Elena Di Nisio
LPLivia Perfetto
Livia Perfetto
Deciphering patient-specific mechanisms of cancer cell reprogramming remains a crucial challenge in systems oncology, as it is key to improving patient diagnosis and treatment. For this reason, comprehensive and patient-specific multi-omic characterization of tumor specimens has become increasingly common in clinical practice. Here, we developed PatientProfiler , a computational workflow that integrates proteogenomic data with curated causal interaction networks to generate mechanistic models of signal transduction for individual patients. PatientProfiler allows multi-omic data analysis and standardization, generation of patient-specific mechanistic models of signal transduction, and extraction of network-based prognostic biomarkers. We successfully benchmarked the tool on proteogenomic and clinical data derived from 122 biopsies of treatment-naïve breast cancer, available through the CPTAC portal. We identified patient-specific mechanistic models that recapitulate oncogenic signaling pathways. In-depth topological exploration of these networks revealed seven subgroups of patients, associated with unique transcriptomic signatures and distinct prognostic values. We identified well-known Basal-like 1 and 2 subtypes, while also highlighting distinct mechanistic drivers such as the MYC–CDK4/6 axis or NF-kappaB-mediated inflammatory programs. Beyond breast cancer, PatientProfiler offers a generalizable framework to transform cohort-level multi-omic data into interpretable mechanistic models, making it applicable across diverse cancer types and other complex diseases.

5 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
VLVeronica Lombardi
Veronica Lombardi
LRLorenzo Di Rocco
Lorenzo Di Rocco
EMEleonora Meo
Eleonora Meo
VVVeronica Venafra
Veronica Venafra
ENElena Di Nisio
Elena Di Nisio
LPLivia Perfetto
Livia Perfetto
Deciphering the intricate mechanisms underlying reprogramming in cancer cells is a crucial challenge in oncology as it holds the key to advance our ability to diagnose and treat cancer patients. For this reason, comprehensive and patient-specific multi-omic characterization of tumor specimens has become increasingly common in clinical practice. While these efforts have advanced our understanding of the molecular mechanisms underlying breast cancer progression, the identification of personalized therapeutic approaches remains a distant goal. The main shortcoming is the absence of a robust computational framework to integrate and interpret the available multi-dimensional data and to drive translational solutions. To fill this gap, we developed PatientProfiler , a computational pipeline that leverages causal interaction data, annotated in our in-house manually-curated resource, SIGNOR, to address how the genetic and molecular background of single patients contributes to the establishment of a malignant phenotype. PatientProfiler is an open-source, R-based package composed of several functions that allows multi-omic data analysis and standardization, generation of patient-specific mechanistic models of signal transduction, and extraction of network-based prognostic biomarkers. To benchmark the tool, we retrieved genomic, transcriptomic, (phospho)proteomic, and clinical data derived from 122 treatment-naïve breast cancer biopsies, available at the CPTAC portal. Thanks to this approach, we identified patient-specific mechanistic models (one patient, one network) that recapitulate dysregulated signaling pathways in breast cancer. This collection of models provides valuable insights into the underlying mechanisms of tumorigenesis and disease progression. Moreover, in-depth topological exploration of these networks has allowed us to define seven communities (subnetworks), each associated with a unique transcriptomic signature and a distinct prognostic value. In summary, our work demonstrates that PatientProfiler is a tool for patient-specific network analysis, advancing personalized medicine towards the identification of actionable biomarkers and tailored therapeutic strategies.